Clinical Trial

Study of ECC4703 With Sulfasalazine and Pitavastatin

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-07-29
Trial Details
NCT Number NCT07726368
Lead Sponsor Eccogene
Conditions Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Enrollment 40 participants
Start Date 2026-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-28